BMYMP News and Press, Bristol-Myers Squibb $2Pr From 01/01/23

Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The Dividend Champions list is a m...

Summary All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 13% and a median increase of 7.6%. There are eight increases for next week, down from twenty-five last week. Happy New Year!...

Summary As most of you know, a high inflation and rising interest rate environment favors defensive sectors that typically outperform in recessionary periods. Healthcare is one such sector. This year, the iShares U.S. Healthcare ETF has outperformed the S&P 500 by 14%. The IYH E...

Summary Ariel Investments’ 13F portfolio value decreased from $10.02B to $9.11B this quarter. They increased Zebra Technologies, Equity Commonwealth, and Generac Holdings while reducing Adtalem Global Education, Snap-on, and J. M. Smucker. The top three positions are Baidu, M...

Summary Karyopharm Therapeutics hasn't done a lot of impressive stuff in the last 6 months. It is trading at 52-week lows, but that may not be a good thing by itself. I will stay on the sidelines, because I am unable to see the value here. I covered Karyopharm Therapeu...

Summary ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action. It has produced solid data. 89Bio ( ETNB ) is one of those NASH stocks that didn’t do too well on Madrigal’s ( MDGL ) success. It fell 30% on...

Summary My passive income was up by 12.03% during November. On a year-to-date basis, my dividends are up by 21.15%. I made 10 trades during November; all purchases. Another month, another step towards financial freedom. During the month of November, my dividend income ...

Summary Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year, and this is mainly due to increased competition from biosimilars in Europe. AbbVie's EBITDA was $7,235 million in Q3 2022, up 2.8% year-on-year. The largest contribution to the company's re...

Summary Focus still remains on advancing balstilimab, but instead of just using it alone as a monotherapy against advanced cancers, it is being moved forward together with botensilimab. The phase 2 ACTIVATE program will use botensilimab either alone or in combination with balstilimab fo...

Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...